Overview

Nintedanib is a small-molecule, multi-targeted tyrosine kinase inhibitor that binds inside the cell to block the enzymatic activity of several receptor tyrosine kinases. In oncology it is used in combination with docetaxel for previously treated advanced non-small cell lung cancer of adenocarcinoma histology, and it is also established in fibrotic interstitial lung diseases. The 100 mg soft capsule is one of the two standard strengths, the other being 150 mg. This article focuses on the molecular mechanism rather than clinical use, explaining which kinases are targeted and why interrupting them matters for tumor angiogenesis and tissue remodeling.

Intracellular Kinase Inhibition Profile

Unlike antibodies that act outside the cell, nintedanib is taken up into cells and competes at the ATP-binding site of its target receptors. Authoritative labeling identifies the principal targets as vascular endothelial growth factor receptors (VEGFR-1, -2, -3), fibroblast growth factor receptors (FGFR-1, -2, -3) and platelet-derived growth factor receptors (PDGFR-alpha and PDGFR-beta). It additionally inhibits certain non-receptor tyrosine kinases such as Src, Lck and Lyn. By occupying the ATP pocket, nintedanib prevents autophosphorylation of these receptors, shutting down the downstream phosphorylation cascades that would otherwise drive cellular growth responses.

Pathways Disrupted in Fibrosis and Angiogenesis

The clinical relevance of this profile comes from the biology these receptors control. VEGF, FGF and PDGF signaling together orchestrate the formation of new blood vessels that tumors co-opt for nutrient supply, and they also stimulate fibroblasts and pericytes during tissue scarring. Blocking these receptors reduces endothelial proliferation and microvessel formation, and it blunts fibroblast activation, migration and the excessive deposition of extracellular matrix proteins such as collagen. In fibrotic lung disease this translates into a slower rate of lung-function decline, while in the tumor setting the anti-angiogenic effect complements cytotoxic chemotherapy. The broad, intracellular action means a single molecule influences several redundant pro-growth pathways at once.

FAQ

Q: Is nintedanib an immunotherapy? A: No. Nintedanib is a small-molecule tyrosine kinase inhibitor, not an immune checkpoint inhibitor or other immunotherapy. It acts directly on intracellular kinase signaling.

Q: Which receptors does nintedanib primarily block? A: Per FDA and EMA labeling, the main targets are VEGFR-1/2/3, FGFR-1/2/3 and PDGFR-alpha/beta, together with several non-receptor kinases such as Src and Lck.

Q: Why does the capsule come in 100 mg and 150 mg strengths? A: The two strengths allow dose individualization; labeling permits temporary or permanent reduction, for example to 100 mg twice daily, when adverse reactions require dose adjustment.